Please assess the completion status of the following clinical trial:

Trial Title: NAC for Head Trauma-induced Anosmia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Ryder Trauma Center for observation acutely following head injury (i.e. concussion), with documented hyposmia or anosmia by University of Pennsylvania Smell Identification Test (SIT).~* Male or female, aged 18 years or older~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Ability to take oral medication and be willing to adhere to the NAC regimen~* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of NAC administration~Exclusion Criteria:~* Severe trauma requiring ongoing inpatient treatment beyond 48 hours~* Pregnancy (based on urine screening) or lactation~* Known allergic reactions to components of NAC, such as Mucomyst~* Currently taking nitrates such as nitroglycerine and/or isosorbide regularly~* Currently taking azathioprine (Imuran) or cyclophosphamide (Cytoxan)~* Known diagnosis of cystinuria (renal condition in which cysteine supplement should be avoided)~* Febrile illness within 1 week~* Treatment with another investigational drug or other intervention within 3 months~* Active sinonasal disease by imaging and/or nasal exam, i.e. rhinosinusitis, nasal polyps~* Adults unable to consent~* Prisoners, employees or subordinates~* Individuals who are not yet adults (infants, children, teenagers). This population is excluded because efficacy has not yet been established in adults.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAC Group (Type: EXPERIMENTAL): NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).